Clopidogrel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Drug Profile

Clopidogrel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Alternative Names: Nanosomal clopidogrel

Latest Information Update: 22 Oct 2015

Price : $50

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Jina Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Antiplatelets; Chlorobenzenes; Esters; Pyridines; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cardiovascular disorders

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 22 Oct 2015 Intas Pharmaceuticals and Jina Pharmaceuticals collaborated in the development of Nanoaqualip™ technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top